Veeva Systems (VEEV)
(Delayed Data from NYSE)
$183.14 USD
-1.87 (-1.01%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $183.26 +0.12 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$183.14 USD
-1.87 (-1.01%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $183.26 +0.12 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Don't Overlook Veeva (VEEV) International Revenue Trends While Assessing the Stock
by Zacks Equity Research
Review Veeva's (VEEV) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Investors Heavily Search Veeva Systems Inc. (VEEV): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both segments.
Veeva (VEEV) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Veeva (VEEV) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Veeva Systems (VEEV) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 4.90% and 1.34%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Pure Storage (PSTG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pure Storage (PSTG) delivered earnings and revenue surprises of 45.45% and 1.78%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Box (BOX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Box (BOX) delivered earnings and revenue surprises of 8.33% and 1.15%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Veeva Systems (VEEV) concluded the recent trading session at $203.89, signifying a -0.34% move from its prior day's close.
Veeva (VEEV) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Get a deeper insight into the potential performance of Veeva (VEEV) for the quarter ended April 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Workday (WDAY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Workday (WDAY) delivered earnings and revenue surprises of 10.83% and 0.84%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems (VEEV) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Veeva Systems (VEEV) closed the most recent trading day at $209.24, moving -0.34% from the previous trading session.
Palo Alto Networks (PANW) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Palo Alto (PANW) delivered earnings and revenue surprises of 5.60% and 0.91%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Masimo's (MASI) New Offering to Serve Personalized Audio Market
by Zacks Equity Research
Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.
Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
by Zacks Equity Research
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
BD's (BDX) FDA-Approved Test to Offer Wider Testing Access
by Zacks Equity Research
BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.
Applied Materials (AMAT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Applied Materials (AMAT) delivered earnings and revenue surprises of 6.09% and 2.04%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Three Reasons to Retain AMN Healthcare (AMN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.
Merit Medical (MMSI) to Expand Product Suite Via New Launch
by Zacks Equity Research
Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.
Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
by Zacks Equity Research
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Why the Market Dipped But Veeva Systems (VEEV) Gained Today
by Zacks Equity Research
In the most recent trading session, Veeva Systems (VEEV) closed at $203.86, indicating a +0.04% shift from the previous trading day.
Three Reasons to Retain Integer Holdings (ITGR) Stock for Now
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.